BRISTOL, Tenn., Feb. 27 /PRNewswire-FirstCall/ -- King Pharmaceuticals,
Inc. (NYSE: KG) today reported that King, Aventis Pharma Deutschland GmbH (now
known as Sanofi-Aventis Deutschland GmbH) and Cobalt Pharmaceuticals, Inc.
have entered into an agreement to dismiss the pending litigation relating to
the enforcement of U.S. Patent Nos. 5,061,722 ("the '722 Patent") and
5,403,856 ("the '856 Patent"). The parties agreed that, subject to certain
conditions, within 38 days of signing the agreement, King, Aventis and Cobalt
will submit a joint stipulation dismissing without prejudice the litigation
before the U.S. District Court for the District of Massachusetts.
Cobalt had sought to market generic versions of Altace(R) (ramipril)
before expiration of the '722 Patent and '856 Patent which relate to Altace(R)
by filing an Abbreviated New Drug Application.
About Altace(R)
Altace(R) is marketed by Monarch Pharmaceuticals, Inc., a wholly owned
subsidiary of King Pharmaceuticals, and Wyeth Pharmaceuticals in the United
States and Puerto Rico pursuant to a co-promotion agreement.
Altace(R) is a leading branded ACE inhibitor with multiple indications.
Altace(R) is indicated for the treatment of hypertension. Altace(R) has also
been shown to reduce the risk of death in stable patients who have
demonstrated clinical signs of congestive heart failure within the first few
days after sustaining acute myocardial infarction. Based upon the results of
the landmark HOPE trial, Altace(R) is also indicated in patients 55 years or
older at high risk of developing a major cardiovascular event either because
of a history of coronary artery disease, stroke or peripheral vascular disease
or because of diabetes that is accompanied by at least one other
cardiovascular risk factor (hypertension, elevated total cholesterol levels,
low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce
the risk of stroke, myocardial infarction, or death from cardiovascular
causes. Altace(R) can be used in addition to other needed treatments (such as
antihypertensive, antiplatelet or lipid-lowering therapies).
Prescription Altace(R) is not for everyone. Altace(R) may cause swelling
of the mouth, tongue, or throat, which could cause extremely serious risk and
requires immediate medical care. Altace(R) may lower blood sugar if taken for
diabetes. A physician should be contacted if one experiences symptoms of low
blood sugar such as sweating or shakiness. Common side effects include
persistent dry cough, dizziness, and light-headedness due to low blood
pressure. Altace(R) should not be taken during pregnancy, as death or injury
to an unborn child may result, or if serious side effects related to previous
ACE inhibitors have occurred.
For a copy of the Altace(R) prescribing information, please visit
http://www.altace.com.
About King Pharmaceuticals
King, headquartered in Bristol, Tennessee, is a vertically integrated
branded pharmaceutical company. King, an S&P 500 Index company, seeks to
capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions, of
novel branded prescription pharmaceutical products in attractive markets and
the strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management.
SOURCE King Pharmaceuticals, Inc.
 back to top
Related links:
http://www.altace.com
http://www.kingpharm.com
Company News On-Call:
http://www.prnewswire.com/comp/120319.html
CONTACT:
James E. Green, Executive Vice President,
Corporate Affairs, +1- 423-989-8125, or David E. Robinson, Senior
Director, Corporate Affairs, +1-423-989-7045, both of King
Pharmaceuticals, Inc.
|
